Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. George on the Clinical Benefit of Phenotypic Evaluation in Prostate Cancer

December 15th 2022

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.

European Commission Approves Pluvicto for PSMA-Positive mCRPC

December 13th 2022

The European Commission has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition, for the treatment of adult patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Practical Considerations for Sequencing Cabazitaxel in Metastatic CRPC

December 12th 2022

Centering discussion on the use of cabazitaxel in metastatic CRPC, key opinion leaders consider optimal sequencing of therapy in light of the TROPIC clinical trial.

Overview on Metastatic CRPC and Available Treatment Options

December 12th 2022

Expert oncologists Tanya Dorff, MD, and Elisabeth Heath, MD, FACP, reflect on the current treatment paradigm for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

December 9th 2022

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Pluvicto Improves rPFS in PSMA-Positive mCRPC

December 5th 2022

Treatment with lutetium Lu 177 vipivotide tetraxetan led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival following treatment with an androgen receptor pathway inhibitor in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Enzalutamide Plus Salvage Radiation Therapy Delays PSA Progression in PSA-Recurrent High-Risk Prostate Cancer

November 30th 2022

Six months of enzalutamide monotherapy in combination with salvage radiation therapy postponed prostate-specific antigen progression compared with SRT alone in men with PSA-recurrent, high-risk prostate cancer.

MHRA Approves Darolutamide Plus ADT and Docetaxel for Metastatic HSPC

November 29th 2022

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved darolutamide tablets in combination with androgen deprivation therapy and docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Precision Medicine Provides Continued Benefit in mCRPC

November 21st 2022

Daniel J. George, MD, discusses the clinical implications use of key trials in metastatic castration-resistant prostate cancer.

Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies

November 19th 2022

Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing.

Technological Advances Specify Optimal Therapies in Prostate Cancer

November 16th 2022

Emerging technologies such as PSMA-PET and magnetic resonance imaging, as well as increasingly refined molecular tests, are strengthening the prostate cancer treatment landscape.

Olaparib Combo Approaches EU Approval for Select Patients With mCRPC

November 14th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib in combination with abiraterone acetate and prednisone or prednisolone for use in adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not indicated.

Dr. Antonarakis on the Benefits of Genetic Testing for Select Patients With Prostate Cancer

November 14th 2022

Emmanuel Antonarakis, MD, discusses the benefits of somatic and germline testing for patients with prostate cancer.

Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing

November 12th 2022

All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications.

Sequencing Considerations in mCRPC Treatment Grow Increasingly Complex

November 11th 2022

For patients with metastatic castration-resistant prostate cancer who experience disease progression on novel hormonal agents (NHAs) and androgen deprivation therapy, it is important to consider when the NHA was received and whether docetaxel has been administered, as these factors affect downstream options and sequencing.

Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer

November 11th 2022

As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.

ADT Alone, With Docetaxel Is Not Enough: ADT Intensification Is SOC for Metastatic Castration-sensitive Prostate Cancer

November 11th 2022

Because androgen deprivation therapy alone or with docetaxel is not recommended for most patients with metastatic castration-sensitive prostate cancer, a decision must be made between leveraging couplets vs triplets.

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

November 11th 2022

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC

November 11th 2022

Emmanuel Antonarakis, MD, discusses the different therapeutic agents that are available for patients with metastatic castration-resistant prostate cancer who display either somatic or germline mutations.

Dr. Shore on the Importance of Genetic Testing in Prostate Cancer

November 11th 2022

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.